File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Recombinant interferon-α in inoperable hepatocellular carcinoma: A randomized controlled trial

TitleRecombinant interferon-α in inoperable hepatocellular carcinoma: A randomized controlled trial
Authors
Issue Date1993
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation
Hepatology, 1993, v. 17 n. 3, p. 389-394 How to Cite?
AbstractTo evaluate the clinical efficacy of interferon-α in hepatocellular carcinoma, 71 adult Chinese patients with histologically proven inoperable hepatocellular carcinoma were randomized to receive recombinant interferon- α(2a) (50 x 106 IU/m2) intramuscularly three times a week (n = 35) or no antitumor therapy (n = 36). The survival of interferon-α-treated patients was significantly better than that of patients who received no antitumor therapy (p = 0.0471); median lengths of survival were 14.5 and 7.5 wk, respectively. Objective tumor regression greater than 50% was observed in 31.4% (11 of 35) of patients receiving interferon-α. Interferon-α induced tumor regression greater than 50% in 11 (31.4%) patients. Compared with the group receiving no antitumor therapy, the interferon-α therapy group had more tumor regression (p < 0.0001) and less tumor progression (p = 0.001). This high-dose interferon-α therapy was relatively well tolerated; only 34.3% of patients required reduction of dosage by one third or one half because of persistent fatigue. Two patients with diabetes mellitus (one also had tabes dorsalis) exhibited mental deterioration that might have been partially attributable to interferon-α therapy. We conclude that interferon- α is useful in a proportion of Chinese patients with inoperable hepatocellular carcinoma, both in prolonging survival and in inducing tumor regression.
Persistent Identifierhttp://hdl.handle.net/10722/162003
ISSN
2015 Impact Factor: 11.711
2015 SCImago Journal Rankings: 4.752

 

DC FieldValueLanguage
dc.contributor.authorLai, CLen_US
dc.contributor.authorLau, JYNen_US
dc.contributor.authorWu, PCen_US
dc.contributor.authorNgan, Hen_US
dc.contributor.authorChung, HTen_US
dc.contributor.authorMitchell, SJen_US
dc.contributor.authorCorbett, TJen_US
dc.contributor.authorChow, AWCen_US
dc.contributor.authorLin, HJen_US
dc.date.accessioned2012-09-05T05:16:34Z-
dc.date.available2012-09-05T05:16:34Z-
dc.date.issued1993en_US
dc.identifier.citationHepatology, 1993, v. 17 n. 3, p. 389-394en_US
dc.identifier.issn0270-9139en_US
dc.identifier.urihttp://hdl.handle.net/10722/162003-
dc.description.abstractTo evaluate the clinical efficacy of interferon-α in hepatocellular carcinoma, 71 adult Chinese patients with histologically proven inoperable hepatocellular carcinoma were randomized to receive recombinant interferon- α(2a) (50 x 106 IU/m2) intramuscularly three times a week (n = 35) or no antitumor therapy (n = 36). The survival of interferon-α-treated patients was significantly better than that of patients who received no antitumor therapy (p = 0.0471); median lengths of survival were 14.5 and 7.5 wk, respectively. Objective tumor regression greater than 50% was observed in 31.4% (11 of 35) of patients receiving interferon-α. Interferon-α induced tumor regression greater than 50% in 11 (31.4%) patients. Compared with the group receiving no antitumor therapy, the interferon-α therapy group had more tumor regression (p < 0.0001) and less tumor progression (p = 0.001). This high-dose interferon-α therapy was relatively well tolerated; only 34.3% of patients required reduction of dosage by one third or one half because of persistent fatigue. Two patients with diabetes mellitus (one also had tabes dorsalis) exhibited mental deterioration that might have been partially attributable to interferon-α therapy. We conclude that interferon- α is useful in a proportion of Chinese patients with inoperable hepatocellular carcinoma, both in prolonging survival and in inducing tumor regression.en_US
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/en_US
dc.relation.ispartofHepatologyen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshCarcinoma, Hepatocellular - Mortality - Radiography - Therapyen_US
dc.subject.meshDrug Administration Scheduleen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshInterferon-Alpha - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshLiver Neoplasms - Mortality - Radiography - Therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshRecombinant Proteinsen_US
dc.subject.meshSurvival Analysisen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleRecombinant interferon-α in inoperable hepatocellular carcinoma: A randomized controlled trialen_US
dc.typeArticleen_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/0270-9139(93)90049-Sen_US
dc.identifier.pmid8383088-
dc.identifier.scopuseid_2-s2.0-0027471332en_US
dc.identifier.volume17en_US
dc.identifier.issue3en_US
dc.identifier.spage389en_US
dc.identifier.epage394en_US
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US
dc.identifier.scopusauthoridLau, JYN=7402446047en_US
dc.identifier.scopusauthoridWu, PC=7403119323en_US
dc.identifier.scopusauthoridNgan, H=7102173824en_US
dc.identifier.scopusauthoridChung, HT=7404007053en_US
dc.identifier.scopusauthoridMitchell, SJ=7402391984en_US
dc.identifier.scopusauthoridCorbett, TJ=7005290843en_US
dc.identifier.scopusauthoridChow, AWC=36729802800en_US
dc.identifier.scopusauthoridLin, HJ=7405571292en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats